Ashley Hammad
Icahn School of Medicine at Mount Sinai
5 Papers
4 Citations
Ashley Hammad is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & Genome editing. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
Thomas U. Marron,M. Isabel Fiel,Pauline Hamon,Nathalie Fiaschi,Edward J. Kim,Stephen C. Ward,Zhen Zhao,Joel Kim,Paul Kennedy,S. Gunasekaran,Parissa Tabrizian,Deborah B. Doroshow,Meredith Legg,Ashley Hammad,Assaf Magen,Alice O. Kamphorst,Muhammed S. Shareef,Namita Gupta,Raquel P. Deering,Wei Wang,Fang Wang,Pradeep Thanigaimani,Jayakumar Mani,Leanna Troncoso,Alexandra Tabachnikova,Christie Chang,Guray Akturk,Mark Buckup,Steven Hamel,G. Ioannou,Clotilde Hennequin,Hajra Jamal,Haley Shae Brown,Antoinette Bonaccorso,Daniel M. Labow,Umut Sarpel,Talia D. Rosenbloom,Max Sung,Baijun Kou,Siyu Li,Vladimir Jankovic,Nicolas James,Sara Hamon,H.-Kam Cheung,Jennifer S. Sims,Elizabeth Miller,Nina Bhardwaj,Gavin Thurston,Israel Lowy,Sacha Gnjatic,Bachir Taouli,Myron Schwartz,Miriam Merad +52 more
TL;DR: In this article , the authors evaluated the clinical activity of neoadjuvant cemiplimab (an anti-PD-1) in patients with resectable hepatocellular carcinoma.
150
A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)
Susan O'Brien,Loretta J. Nastoupil,James Essell,Ly Dsouza,Doug Hart,Emiri Matsuda,Tarah Satterfield,Tonia Nesheiwat,Ashley Hammad,Franco Davi,Shally Chung,S. A. Shamsi,Mara Bryan,Justin Skoble,E. Garner,Steven Kanner,Syed W H Rizvi,Houston Holmes +17 more
TL;DR: CAR-T cell therapies have shown significant benefit in the treatment of adults with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL) as discussed by the authors .
13
Abstract CT182: Neoadjuvant cemiplimab demonstrates complete pathological responses in hepatocellular carcinoma
Thomas U. Marron,Ganesh Gunasekaran,Parissa Tabrizian,Edward Kim,Maria Isabel Fiel,Stephen C. Ward,Zhen Zhao,Deborah B. Doroshow,Meredith Legg,Ashley Hammad,Paul Kennedy,Guray Akturk,Pauline Hamon,Antoinette Bonaccorso,Daniel M. Labow,Sacha Gnjatic,Bachir Taouli,Elizabeth Miller,Pradeep Thanigaimani,Nathalie Fiaschi,Jennifer Sims,Jayakumar Mani,Nicola James,Sara Hamon,Vladimir Jankovic,Siyu Li,Hung Kam Cheung,Gavin Thurston,Israel Lowy,Myron Schwartz,Miriam Merad +30 more
TL;DR: Marron et al. as discussed by the authors conducted a trial of perioperative cemiplimab (anti-PD-1) for resectable hepatocellular carcinoma (HCC).
5
Financial toxicity in patients with advanced solid malignancies participating in early-phase clinical trials.
Julia Blanter,Michael Werner,M. Kier,Olivia Hapanowicz,Muhieddine M. Itani,Maham Ahmad,Mandy DeMerchant,Joseph Paul Eder,Matthew D. Galsky,Ashley Hammad,P King,Michael Lachowicz,Natalie C. Lucas,Thomas U. Marron,Gary Shelton,Kathy Wu,Suzanne Xu,Patricia LoRusso,Erin Hofstatter,Deborah B. Doroshow +19 more
TL;DR: Baseline FT was higher among pts < 65 years of age, primary wage earners, and those who managed household finances independently, and retirement was a protective factor, which may be explained by the life savings often required to retire.
A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).
Jesus G. Berdeja,Thomas R. Martin,Adriana C Rossi,James Essell,David Spiegel,Sham Mailankody,Neeraj Saini,Houston Holmes,Binod Dhakal,Cristina Gasparetto,Samir Parekh,S. Portella,Guy Ledergor,Ashley Hammad,Franco Davi,Justin Skoble,E. Garner,Steven B. Kanner,Syed W H Rizvi,Sundar Jagannath +19 more
TL;DR: CB-011 as discussed by the authors is an allogeneic, off-the-shelf anti-BCMA CAR-T cell therapy derived from healthy donor T cells using CRISPR hybrid RNA-DNA (chRDNA) guides.